Stephen D Shafran
Overview
Explore the profile of Stephen D Shafran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shafran S, Hughes C
HIV Med
. 2022 Aug;
24(3):361-365.
PMID: 35973753
Background: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B/F/TAF in patients with nucleoside reverse transcriptase inhibitor...
2.
3.
Parmar P, Shafran S, Borgia S, Doucette K, Cooper C
JGH Open
. 2021 Feb;
5(2):253-257.
PMID: 33553664
Background And Aim: Elderly patients with hepatitis C virus (HCV) infection have worse interferon-based treatment outcomes than young patients. Direct-acting antiviral (DAA) regimens have enabled the treatment of previously difficult-to-cure...
4.
Round J, Savaryn B, Plitt S, Shafran S, Charlton C
Ann Hepatol
. 2020 Nov;
23:100283.
PMID: 33217588
Introduction: With the availability of direct-acting antivirals, Hepatitis C (HCV) is now considered a treatable disease. Patients who are co-infected with human immunodeficiency virus (HIV) and HCV represent an ideal...
5.
Mangia A, Milligan S, Khalili M, Fagiuoli S, Shafran S, Carrat F, et al.
Liver Int
. 2020 May;
40(8):1841-1852.
PMID: 32449966
Background And Aims: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis...
6.
Asselah T, Shafran S, Bourgeois S, Lai C, Mathurin P, Willems B, et al.
J Viral Hepat
. 2019 Jun;
26(10):1229-1232.
PMID: 31216086
Sofosbuvir-velpatasvir is approved for the treatment of chronic hepatitis C virus (HCV) infection. In this single-arm, open-label, phase 3, deferred treatment study, we investigated the efficacy and safety of sofosbuvir-velpatasvir...
7.
Borgia S, Dearden J, Yoshida E, Shafran S, Brown A, Ben-Ari Z, et al.
J Hepatol
. 2019 Jun;
71(4):660-665.
PMID: 31195062
Background & Aims: Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD),...
8.
Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran S, et al.
Open Forum Infect Dis
. 2019 Apr;
6(3):ofz076.
PMID: 30949527
Background: Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86 subtypes. The objective of this study was to characterize novel HCV subtypes and to investigate the impact...
9.
10.
Poordad F, Shiffman M, Ghesquiere W, Wong A, Huhn G, Wong F, et al.
Antivir Ther
. 2018 Nov;
24(1):35-44.
PMID: 30382942
Background: Optimal treatment for patients with HCV genotype-3 infection and liver cirrhosis remains a medical priority. Daclatasvir+sofosbuvir and ribavirin is a recommended option for such patients, but clinical trial data...